Articles tagged with Parkinsons Disease
Researchers at OHSU discovered adenosine effectively acts as a brake to dopamine, promoting balance in neuronal signaling. This finding suggests new avenues for drug development to treat Parkinson's disease symptoms by targeting the push-pull dynamic between dopamine and adenosine.
A team of researchers has deciphered the molecular mechanism linked to juvenile Parkinson's disease, a genetic mutation affecting the adenosine type 1 receptor gene. The mutation alters the interaction between adenosine receptors, leading to increased neuronal circuit excitability in the brain region striatum.
A randomized controlled trial found that oral ENT-01 significantly improves constipation and possibly neurological symptoms in persons with Parkinson disease. The treatment is safe for up to 25 days, with a dose-dependent effect that persists beyond the treatment period.
A University of Colorado study reveals aggressive behavior towards caregivers is a significant issue in Parkinson's disease, with factors including grief, loss of motor symptoms, and cognitive fluctuations identified as contributing to the problem. The research also highlights the impact on caregivers' mental health and relationships.
Researchers have developed a new gene therapy that selectively targets overactive brain cells, reducing excitability and suppressing seizures in mice. The treatment shows promise for treating neurological disorders such as epilepsy, Parkinson's disease, schizophrenia, and pain disorders.
Researchers have discovered that mutations in mitochondrial-related genes can trigger hyperinflammation, leading to diseases such as Crohn's disease and tuberculosis. The study found that these mutations lead to a new type of cell death called necroptosis, which causes an aggressive inflammatory immune response.
Research suggests exercise-induced activation of peripheral systems, such as muscle, gut, and liver, may affect neural plasticity and cognitive health. Circulating cathepsin B (CTSB) and brain-derived neurotrophic factor (BNDF) have been found to possess robust neuroprotective effects.
A new computational model based on fruit fly brain data may help explain how humans process memories and experiences. The model suggests that living organisms, including humans, use a similar '1-2-3-many' count sketch to track encounters with familiar sights and smells.
Researchers will investigate immune system differences between men and women to better understand neurodegenerative diseases. The study aims to identify why certain neurological diseases primarily affect males or females, and how this difference impacts disease progression.
Researchers identified a compound that reverses damage to brain cells caused by Parkinson's disease and breaks a self-sustaining molecular loop between LRRK2 and AICD. The potential drug itanapraced has passed safety tests and could improve quality of life for those afflicted with PD and Alzheimer's disease.
A study published in Neurology found that people with Parkinson's disease who gained weight had slower declines in thinking skills compared to those who lost weight. Weight management may play a crucial role in slowing cognitive decline in early Parkinson's.
Researchers identified a kinase molecule that directs microglia activity, potentially treating neurodegenerative diseases like Alzheimer's and MS. The molecule, called spleen tyrosine kinase, targets plaque buildup and debris accumulation in the brain.
Researchers discovered more than 200 genes with different epigenetic marks in Parkinson's disease brain neurons, but the affected genes were almost entirely different in men and women. The study opens up new avenues for investigation into how these genes contribute to the disease.
Researchers have discovered that zinc ions tune the ability of human serum albumin to prevent α-synuclein aggregation, a process linked to Parkinson's disease. Zinc binding alters HSA's chaperone function, blunting fibril formation and slowing down protein deposition that can lead to neurodegeneration.
Researchers have identified cognitive impairment in patients with dementia-related diseases up to 9 years before diagnosis, raising hope for earlier interventions and clinical trial recruitment. The study analyzed UK Biobank data and found subtle impairments in problem-solving and memory across various conditions.
A team of researchers used digital cameras and machine learning algorithms to develop a system that can predict gait dysfunctions in people with multiple sclerosis and Parkinson's disease. The study revealed that several algorithms were over 75% accurate at detecting differences between those with the conditions and those without.
A new screening test App can produce accurate results using just people's voice recordings, improving the management of Parkinson's disease and severe COVID-19. The smartphone App takes just 10 seconds to reveal whether a person may have Parkinson’s disease and should be referred to a neurologist.
Researchers from the University of Cincinnati found that low levels of soluble amyloid-beta protein in the brain, rather than its buildup into plaques, are associated with cognitive decline and Alzheimer's disease. Patients with high levels of soluble amyloid-beta showed improved cognitive outcomes, contradicting previous theories.
The National Institutes of Health has awarded a $10.7 million grant to Cleveland Clinic to expand a national research consortium focused on improving diagnosis and treatments for Dementia with Lewy Bodies. The consortium, which includes multiple clinical sites, aims to identify biomarkers for disease and develop new therapies.
Researchers developed a machine learning model to quickly recognize predictive risk factors and their importance for undesirable hospitalization outcomes. The model achieved an accuracy of 95.6% and identified modifiable risk factors that can be mitigated through clinical interventions.
Researchers from Xi'an Jiaotong-Liverpool University found that brain stimulation combined with a nose spray containing nanoparticles can improve recovery after ischemic stroke. The treatment increased cognitive and motor functions, and weighed more quickly than those treated with TMS alone.
New research shows that COVID-19 infections can lead to a range of neurological complications in the first year after infection, including strokes, cognitive decline, depression, anxiety, and migraine headaches. The study analyzed over 14 million medical records and found that COVID-19 survivors were at increased risk of developing the...
Researchers have successfully created dopaminergic neurons directly from the skin of patients with Parkinson's disease, preserving aged characteristics and cellular defects. This breakthrough allows for modeling PD-related neuronal defects in a larger cohort of patients, aiming to identify disease causes and potential therapies.
Researchers developed an in-home wireless device that monitors a patient's movement and gait speed to track Parkinson's disease progression. The device uses machine-learning algorithms to analyze over 200,000 data points collected from 50 participants, showing that it can effectively track the severity of the disease.
A new study reveals that aggregates of the protein alpha-synuclein spread in the brains of people with Parkinson's disease through a cellular waste-ejection process called lysosomal exocytosis. This process can lead to the deaths of neurons and ultimately result in the characteristic symptoms of the disease.
A new study published in PLOS Medicine found that people with hospital-treated infections in early- and mid-life had a higher risk of developing Alzheimer's disease (AD) and Parkinson's disease (PD). The research analyzed data on over 291,000 cases and matched controls to identify the association between infections and neurodegenerativ...
A University of Ottawa research team has made new discoveries on how motor skills are learned and stored in the brain. By studying mice, they found that a specific transcription factor called NPAS4 regulates gene changes in inhibitory neurons, leading to the formation of learning-associated neuron ensembles.
Researchers from Johns Hopkins Medicine and Dana Farber Cancer Institute found that irisin reduces levels of a protein linked to Parkinson's disease and halts movement problems in mice. Irisin also speeds up the transport and degradation of alpha synuclein via fluid-filled sacs called lysosomes in brain cells.
Researchers discovered a gene called nervy that helps fruit flies respond to socio-environmental signals to stop fighting. The study's findings have implications for understanding aggression in humans and potentially treating psychiatric disorders like Parkinson's disease.
Scientists at the Francis Crick Institute discovered how a build-up of harmful protein starts to happen within neurons in Parkinson's disease. The research found that misfolded alpha-synuclein clumps on the surface of mitochondria, causing holes and interfering with energy production.
A study found that inactivating a specific protein complex, PRC2, leads to impaired gene silencing and loss of neurotransmitter production in nerve cells. This is linked to Parkinson's disease-like symptoms and mental health problems.
Researchers at MIT developed an AI model that can detect Parkinson's disease from breathing patterns, using a neural network to assess the presence and severity of the condition. The device is non-invasive and can be used in patients' homes without any bodily contact.
Research reveals that physical activity has a noticeable effect on almost all brain regions, with higher intensity and duration increasing brain volume and cortical thickness. The hippocampus, a key memory center, benefits most from physical activity, which can help counteract age-related loss of brain matter.
Researchers found substantial iron deposits in motor circuits of the brain in individuals with high genetic risk for hereditary hemochromatosis, increasing risk for Parkinson's disease and other movement disorders. Males were more affected than females due to natural processes.
Researchers have created a nanobody that can penetrate tough brain cell coatings and disrupt alpha-synuclein clumps, which contribute to neurodegenerative diseases. The nanobody, PFFNB2, shows promise in preventing disease progression in live mouse brains.
A new study finds that COVID-19 infections may predispose individuals to developing irreversible neurological conditions, such as Alzheimer's and Parkinson's diseases. The research also suggests that the virus can cause long-term neurodegenerative diseases, particularly in the elderly and other vulnerable populations.
University of Iowa researchers confirmed a specific brain region, the subthalamic nucleus, plays a critical role in governing mind-body communication for motor control. The study could advance treatment options for Parkinson's disease, a disorder characterized by declining motor coordination.
A genetic defect in flies leads to motor disorders, similar to those found in humans with Parkinson's disease. The study suggests that Creld, a protein involved in energy production, may play an important role in the development of Parkinson's.
A team of scientists has discovered a key link between the protein αSyn and Parkinson's disease, finding that it interacts with immune responses in neurons. This interaction may play a critical role in the development of the disease, suggesting a potential new approach for treatments by targeting inflammatory pathways.
Researchers at Hebrew University have developed a new method using quantitative MRI to diagnose early-stage Parkinson's disease. This technique reveals biological changes in the brain, enabling early diagnosis and monitoring of treatment efficacy.
A study of almost 21,000 people found that moderate drinking is associated with higher iron levels in the brain and poorer cognitive function. Iron accumulation is a potential mechanism for alcohol-related cognitive decline, which can lead to Alzheimer's and Parkinson's diseases.
Researchers at SFU have developed new chemical biological tools to monitor Parkinson’s disease progression, measuring the activity of lysosomal glucocerebrosidase (GCase) enzyme. This breakthrough could lead to improved diagnostics and treatment, as well as a better understanding of other neurodegenerative diseases linked to GCase.
The article discusses global disparities in Parkinson disease, identifying six key areas for improvement: disease burden, advocacy and awareness, prevention and risk reduction, diagnosis, treatment, and care, caregiver support, and research. These findings aim to inform policy decisions and drive action towards reducing health inequities.
A UBC Okanagan study published in Nature-Scientific Reports found that regular small amounts of psilocybin improved mood, mental health, and psychomotor ability in participants. Microdosing was associated with reduced symptoms of depression, anxiety, and stress, particularly among those over 55.
Researchers discovered that copper accelerates protein aggregation in Parkinson's disease, forming ring-shaped structures that can be used as therapeutic targets. The study provides new clues to the development of the neurodegenerative disease.
A recent study published in Movement Disorders found that a buildup of TDP-43 protein may be responsible for PD-related cell death. This discovery suggests a new cause of the disease and could lead to the development of new treatments.
A new study found that specific gene mutations, such as LRRK2 and PRKN, may prolong survival time in Parkinson's patients, while SNCA and GBA mutations may shorten it. This could lead to more personalized treatment plans for patients with these genetic variants.
Researchers found that COVID-19 positive individuals had a higher risk of developing Alzheimer’s disease, Parkinson’s disease, and ischaemic stroke compared to those who tested negative. The study also revealed increased risks for intracerebral haemorrhage and decreased frequencies for other neurodegenerative illnesses.
Researchers used microcircuit models of basal ganglia and thalamus areas to create multiscale models of Parkinson's patient and healthy control brain. They found that in-silico deep brain stimulation could normalize decreased firing rates in subcortical regions, but also caused differential activity in the motor cortex.
Researchers at Brigham and Women's Hospital have identified LIPE, a lipase that degrades triglycerides, as a promising candidate therapeutic target for Parkinson's disease. Inhibiting LIPE reduced alpha-synuclein inclusions and alleviated neurodegeneration in patient-derived neurons and a C. elegans model of toxicity.
A study led by Brigham and Women's Hospital investigators has revealed that alpha-synuclein plays a dual role in Parkinson's disease, interacting with both vesicles and P-body structures. This new understanding may lead to targeted treatments for the disease, with ongoing genetic studies aiming to identify optimal therapeutic targets.
Researchers at USC Dornsife College of Letters, Arts and Sciences have elucidated the structure of a small protein carrying GABA into neurons using cryogenic electron microscopy. This breakthrough could lead to more effective drugs for conditions such as epilepsy, bipolar disorder, schizophrenia, Parkinson's disease, and autism spectru...
Researchers have identified three distinct brain circuits in the thalamus that contribute to Parkinson's disease symptoms, including motor dysfunction and depression. By manipulating these circuits, they were able to reverse Parkinson's symptoms in mice, suggesting potential new therapeutic targets.
A new study published in eClinicalMedicine found that older men experiencing frequent bad dreams were twice as likely to be diagnosed with Parkinson's disease. The researchers suggest that dream changes could serve as an early warning sign for the condition, which may develop years before characteristic symptoms appear.
Researchers at Johns Hopkins Medicine identified a chemical compound that stops the final events in the pathway linked to brain cell death in Parkinson’s disease. The compound, PAANIB-1, blocks the protein parthanatos without affecting its other critical activities, potentially halting neurodegenerative progression.
Researchers at the University of Warwick have identified a novel cellular process called Golgiphagy that helps regulate the degradation of the Golgi complex in cells. This discovery opens new avenues for understanding the underlying mechanisms of diseases such as cancer, Alzheimer's, and Parkinson's.
Researchers at Kobe University and Hiroshima University have developed a biomarker that can diagnose Parkinson's disease from blood serum samples. The 'P450 inhibition assay' uses 12 different human P450s to detect changes in metabolites, allowing for accurate diagnosis with an accuracy rate of 85-88%. This breakthrough could lead to f...
A new study by the University of Birmingham found that dopamine levels can affect emotion recognition in people with neurological disorders. Those with low baseline dopamine levels improved their ability to recognize emotions after receiving a dopamine boost, while those with higher baseline levels became worse at emotion recognition.
A novel preclinical drug has been developed to inhibit the kinase enzyme Cdk5, which is implicated in neuropsychiatric and neurodegenerative conditions. The drug, 25-106, is brain-permeable and shows promise in altering neurobehavior in mice with anxiety-like behavior.
A Johns Hopkins Medicine study found that a protein called STING responds to clean-up signals in brain cells damaged by Parkinson’s disease by creating a cycle of inflammation that accelerates the disease’s progression. In mice with deactivated STING proteins, there was less microglial activity and brain cell death.